<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012775</url>
  </required_header>
  <id_info>
    <org_study_id>RINPH-IM</org_study_id>
    <nct_id>NCT04012775</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Rinsulin® NPH (&quot;Geropharm&quot;, Russia) With Humulin® NPH (&quot;Lilly France&quot;, France) in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to approve non-inferior efficacy and safety of Rinsulin® NPH compared
      to Humulin® NPH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in titer of antibodies to human insulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes (glucose level &lt; 3.9 mmol/l) frequency</measure>
    <time_frame>28 weeks (4 + 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>28 weeks (4 + 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Injection Site Reaction</measure>
    <time_frame>28 weeks (4 + 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose level from baseline</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose level from baseline</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose level from baseline</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basal insulin dose per body weight (U/kg) from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total basal insulin dose (U) from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Humulin® NPH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Rinsulin® NPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Humulin® NPH</intervention_name>
    <description>4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses</description>
    <arm_group_label>Insulin Humulin® NPH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Rinsulin® NPH</intervention_name>
    <description>4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses</description>
    <arm_group_label>Insulin Rinsulin® NPH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written consent

          -  Diabetes mellitus type 2

          -  Indications for Rinsulin NPH / Humalog NPH treatment

          -  Glycosylated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values
             inclusive)

          -  Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive).

          -  Female patients of childbearing potential who are willing to use two acceptable
             methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel
             plus condom, diaphragm plus condom, etc.), from the time of screening and for the
             duration of the trial, through trial completion.

        Exclusion Criteria:

          -  Age less than 18 years old at screening

          -  Pregnant and breast-feeding women

          -  Need of administration of glucocorticoid therapy or any other therapy that may
             influence glucose level

          -  Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum)

          -  Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg),
             hepatitis C (HCVAb) or antibodies to Treponema pallidum (syphilis) at screening.

          -  History of hypersensitivity to any of the active or inactive ingredients of the
             insulin/insulin analogue preparations used in the trial, OR history of significant
             allergic drug reactions.

          -  History of hematological disorders that can affect the reliability of HbA1c estimation
             (hemoglobinopathies, hemolytic anemia, etc.).

          -  History or presence of a medical condition or disease that in the investigator's
             opinion would embarrass glycemic control and completion of the study

          -  Presence of severe diabetes complications

          -  Receipt of another investigational drug in the 3 months prior to screening

          -  Acute psychiatric disorder or exacerbation of chronic psychiatric disorder at
             screening

          -  History or presence of drug abuse

          -  Positive test for addictive substance in urine at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga A Miroshnichenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Petersburg State Diagnostic Center № 85</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelyabinsk Railway Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Endocrinological Dispensary</name>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Hospital № 71</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Regional Clinical Hospital</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.A. Baranov Republic Hospital</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic № 6</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192148</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital № 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic № 17</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195176</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Sanitary Unit № 157</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Research</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Eco-Safety</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Diagnostic Center № 85</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Center</name>
      <address>
        <city>Samara</city>
        <zip>443067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital № 3</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

